Skip to main content
. 2021 Jun 2;8:658747. doi: 10.3389/fmed.2021.658747

Figure 8.

Figure 8

Cost-effectiveness acceptability curves for abemaciclib plus fulvestrant vs. palbociclib plus fulvestrant, ribociclib plus fulvestrant and fulvestrant monotherapy. ABE, abemaciclib; RIB, ribociclib; PAL, palbociclib; FUL, fulvestrant; WTP1, $50,000; WTP2, $100,000; WTP3, $200,000.